88611-67-0

Basic information

• Product Name: N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide
• Synonyms: 6-ACETAMIDO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-ONE;N1-(5-OXO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)ACETAMIDE;6-Acetamido-1,2,3,4-tetrahydronaphthalen-1-one 97%;6-ACETAMIDO-1,2,3,4-TETRAHYDRONAPHTHALENE-1-ONE;N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide;6-Acetamido-1,2,3,4-tetrahydronaphthalen-1-one97%;N-(5-Oxo-5,6,7,8-tetrahydrophthalen-2-yl)acetamide;N-(5-oxo-7,8-dihydro-6H-naphthalen-2-yl)acetamide
• CAS NO: 88611-67-0
• Molecular Formula: C₁₂H₁₃NO₂
• Molecular Weight: 203.24
• Product Categories: Fused Ring Systems
• Mol File: 88611-67-0.mol

Chemical Properties

• Melting Point: 127 °C
• Boiling Point: 439.6 °C at 760 mmHg
• Flash Point: 193.5 °C
• Appearance: /
• Density: 1.225g/cm³
• Vapor Pressure: 6.27E-08mmHg at 25°C
• Refractive Index: 1.609
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.56±0.20(Predicted)
• CAS DataBase Reference: N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide(88611-67-0)
• EPA Substance Registry System: N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide(88611-67-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 24/25
• Hazardous Substances Data: 88611-67-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide is used as a research compound for its potential pharmaceutical applications, primarily due to its biological activities and effects on the central nervous system. It is studied for its potential as a therapeutic agent in the treatment of various neurological disorders.
Used in the Study of Central Nervous System Effects:
In the field of neuroscience, N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide is used as a tool to investigate its impact on the central nervous system. Its effects are of interest to researchers seeking to understand and potentially treat neurological conditions.
Used in Drug Development for Neurological Disorders:
N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide is utilized as a candidate for drug development, with the aim of creating new treatments for neurological disorders. Its potential as a therapeutic agent is being explored, which could lead to advancements in medical treatments for such conditions.

InChI:InChI=1/C12H13NO2/c1-8(14)13-10-5-6-11-9(7-10)3-2-4-12(11)15/h5-7H,2-4H2,1H3,(H,13,14)

Upstream product

• 50878-03-0 N-(5,6,7,8-tetrahydronaphth-2-yl)acetamide 
• 3470-53-9 6-amino-1-tetralone 
• 75-36-5 acetyl chloride 
• 6328-00-3 4-(3-nitro-phenyl)-4-oxo-butyric acid 
• 2051-95-8 succinylbenzene 
• 14714-31-9 β-<3-Acetylamino-benzoyl>-propionsaeure 
• 108-24-7 acetic anhydride 

Downstream Products

• 3470-53-9 6-amino-1-tetralone 
• 1000300-19-5 ((R)-6-chlorosulfonyl-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-carbamic acid benzyl ester 
• 1000300-17-3 ((R)-6-iodo-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-carbamic acid benzyl ester 
• 895534-29-9 (S)-6-iodo-1,2,3,4-tetrahydro-naphthalen-1-ol 
• 103796-57-2 6-amino-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid 
• 66361-80-6 6-(methylsulfonylamino)-1-tetralone 
• 138814-34-3 6-(acetylamino)-7-nitro-1-<<4-(phenylsulfonyl)phenyl>thio>-1,2,3,4-tetrahydronaphthalene 
• 138814-35-4 6-amino-7-nitro-1-<<4-(phenylsulfonyl)phenyl>thio>-1,2,3,4-tetrahydronaphthalene 
• 138834-44-3 2-amino-5-<<4-(phenylsulfonyl)phenyl>thio>-5,6,7,8-tetrahydronaphth<2,3-d>imidazole 
• 138814-36-5 6,7-diamino-1-<<4-(phenylsulfonyl)phenyl>thio>-1,2,3,4-tetrahydronaphthalene 
• 88285-36-3 N-[6-(4-Benzhydryl-piperazin-1-ylmethyl)-7,8-dihydro-naphthalen-2-yl]-butyramide 
• 88285-33-0 N-[6-(4-Benzhydryl-piperazin-1-ylmethyl)-7,8-dihydro-naphthalen-2-yl]-acetamide 
• 88285-39-6 1-benzhydryl-4-(7-methylsulfonylamino-1,2-dihydro-3-naphthyl)-methylpiperazine 

Relevant articles and documents

Ratiometric fluorescence assay for nitroreductase activity: Locked-Flavylium fluorophore as a NTR-sensitive molecular probe

Nitroreductases belong to a member of flavin-containing enzymes that can reduce nitroaromatic compounds to amino derivatives with NADH as an electron donor. NTR activity is known to be elevated in the cancerous environment and is considered an advantageous target in therapeutic prodrugs for the treatment of cancer. Here, we developed a ratiometric fluorescent molecule for observing NTR activity in living cells. This can provide a selective and sensitive response to NTR with a distinct increase in fluorescence ratio (FI530/FI630) as well as color changes. We also found a significant increase in NTR activity in cervical cancer HeLa and lung cancer A549 cells compared to non-cancerous NIH3T3. We proposed that this new ratiometric fluorescent molecule could potentially be used as a NTR-sensitive molecular probe in the field of cancer diagnosis and treatment development related to NTR activity.

Practical Synthesis of (3a R, 9b R)-8-Fluoro-7-(perfluoropropan-2-yl)-9b-(phenylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1 H-benzo[e]indole: An Advanced Intermediate to Access the RORγt Inverse Agonist BMT-362265

A practical and scalable route to (3aR, 9bR)-8-fluoro-7-(perfluoropropan-2-yl)-9b-(phenylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indole 10, an advanced intermediate en route to the synthesis of the RORγt inverse agonist, BMT-362265, is described starting from fluorobenzene. The synthesis involved the screening of multiple synthetic routes for their feasibility and scalability. We also demonstrate the utility of an annulating reagent, (R)-N-(2-chloroethyl)-2-methylpropane-2-sulfinamide, for the diastereoselective synthesis of tricyclic pyrrolidine intermediates 24 and 36 on a multigram scale.

Discovery, synthesis, and structure-activity relationship of 6-aminomethyl-7,8-dihydronaphthalenes as human melanin-concentrating hormone receptor 1 antagonists

Human melanin-concentrating hormone receptor 1 (hMCHR1) antagonists are promising targets for obesity treatment. We identified the tetrahydronaphthalene derivative 1a with modest binding affinity for hMCHR1 by screening an in-house G protein-coupled receptor (GPCR) ligand library. We synthesized a series of 6-aminomethyl-5,6,7,8-tetrahydronaphthalenes and evaluated their activity as hMCHR1 antagonists. Modification of the biphenylcarbonylamino group revealed that the biphenyl moiety played a crucial role in the interaction of the antagonist with the receptor. The stereoselective effect of the chiral center on binding affinity generated the novel 6-aminomethyl-7,8-dihydronaphthalene scaffold without a chiral center. Optimization of the amino group led to the identification of a potent antagonist 2s (4′-fluoro-N-[6-(1- pyrrolidinylmethyl)-7,8-dihydro-2-naphthalenyl][1,1′-biphenyl] -4-carboxamide), which significantly inhibited the nocturnal food intake in rats after oral administration. Pharmacokinetic analysis confirmed that 2s had good oral bioavailability and brain penetrance. This antagonist appears to be a viable lead compound that can be used to develop a promising therapy for obesity.

SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS

The present invention relates to substituted imidazoly 1-5,6- dihydrobenzo[n]isoquinoline compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted imidazolyl-5,6-dihydrobenzo[n]isoquinoline compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

ORGANIC COMPOUNDS

The present invention provides a compound of formula I: said compound is inhibitor of aldosterone synthase (CYP11B2), and/or 11beta-hydroxylase (CYP11B1), and/or aromatase, and thus can be employed for the treatment of a disorder or disease mediated by al

Monoquaternary neuromuscular blocking agents based on 1 tetralone and 1 indanone

The preparation of three isomeric 1 tetralone hydrazones and three isomeric 1 indanone hydrazones possessing a single quaternary ammonium center is described. Several of the compounds possessed significant neuromuscular blocking activity, and two approached suxamethonium in potency. 1H NMR evidence obtained from a study of the N,N dimethylhydrazones indicated that the hydrazones adopted an E configuration in solution.